Fluoroquinolone-resistant Neisseria gonorrhoeae: The inevitable epidemic

Research output: Contribution to journalArticle

Abstract

The worldwide incidence of fluoroquinolone-resistant Neisseria gonorrhoeae has increased dramatically in the last few years. Single doses of fluoroquinolones can no longer be used to treat N gonorrhoeae infections acquired in the Far East, parts of the Middle East, the Pacific Islands, and parts of Western Europe and the United States. Although California and Hawaii account for most of the current United States cases, the increased incidence of FQR in some high-risk groups independent of geography heralds an imminent spread of drug-resistant strains throughout the rest of the population. The use of molecular tests has revolutionized the diagnostic field in STIs. The main limitation of their application in N gonorrhoeae testing has been the loss of culture specimens that allow antimicrobial sensitivity testing. New molecular methods have made it possible to detect antimicrobial resistance without the use of live organisms. These tests hold the promise of improving epidemiologic tracking of N gonorrhoeae drug resistance, leading to better patient management at the local level. The loss of fluoroquinolones limits available oral regimens to a single CDC-recommended antibiotic, cefixime. Oral, inexpensive, single-dose alternatives are needed to ensure continued therapeutic success.

Original languageEnglish (US)
Pages (from-to)351-365
Number of pages15
JournalInfectious Disease Clinics of North America
Volume19
Issue number2 SPEC. ISS.
DOIs
Publication statusPublished - Jun 2005

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this